Zobrazeno 1 - 10
of 221
pro vyhledávání: '"A. S. Asch"'
Autor:
D. A. Sallman, M. M. Al Malki, A. S. Asch, E. S. Wang, J. G. Jurcic, T. J. Bradley, I. W. Flinn, D. A. Pollyea, S. N. Kambhampati, T. N. Tanaka, J. F. Zeidner, G. Garcia-Manero, D. Jeyakumar, L. Gu, A. Tan, M. Chao, C. O’Hear, I. Lal, P. Vyas, N. Daver
Publikováno v:
HemaSphere, Vol 6, Pp 67-68 (2022)
Externí odkaz:
https://doaj.org/article/f11a8ee031f8479881eff9499ea7ccf4
Publikováno v:
Cells, Vol 13, Iss 17, p 1463 (2024)
Bladder cancer (BCa) is one of the most lethal genitourinary malignancies owing to its propensity for recurrence and poor survival. The biochemical pathway, signal transducer and activator of transcription 3 (STAT3), has gained significance as a mole
Externí odkaz:
https://doaj.org/article/fb84af2f6a7c4053877f9c9f1c961f7c
Autor:
Joshua M. Corbin, Constantin Georgescu, Lin Wang, Jonathan D. Wren, Magdalena Bieniasz, Chao Xu, Adam S. Asch, Maria J. Ruiz Echevarría
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 257-272 (2023)
Blocking androgen receptor signaling is the mainstay of therapy for advanced prostate cancer (PCa). However, acquired resistance to single agents targeting this pathway results in the development of lethal castration-resistant PCa. Combination therap
Externí odkaz:
https://doaj.org/article/41fabf28d4364d8697b56a2f8a9cd7e7
Autor:
Lisa Johnson, Yajia Zhang, Linda Su-Feher, Yeonju Lee, David A. Sallman, Adam S. Asch, Monzr M. Al Malki, Hyunjae Ryan Kim
Publikováno v:
HemaSphere, Vol 7, p e45153c5 (2023)
Externí odkaz:
https://doaj.org/article/5e14c20208aa474dbe439319678e09ee
Autor:
I. Ghanzouri, S. Amal, V. Ho, L. Safarnejad, J. Cabot, C. G. Brown-Johnson, N. Leeper, S. Asch, N. H. Shah, E. G. Ross
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Peripheral artery disease (PAD) is a common cardiovascular disorder that is frequently underdiagnosed, which can lead to poorer outcomes due to lower rates of medical optimization. We aimed to develop an automated tool to identify undiagnose
Externí odkaz:
https://doaj.org/article/5141c8c5477348d6b52854b8315fc3d0
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Genomic instability (GI) in cancer facilitates cancer evolution and is an exploitable target for therapy purposes. However, specific genes involved in cancer GI remain elusive. Causal genes for GI via expressions have not been comprehensivel
Externí odkaz:
https://doaj.org/article/469da7247fcd443ba2cfc8a145e2b8a3
Autor:
Joshua M. Corbin, Constantin Georgescu, Jonathan D. Wren, Chao Xu, Adam S. Asch, Maria J. Ruiz-Echevarría
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 24, Iss , Pp 337-351 (2021)
Resistance to anti-androgen therapy in prostate cancer (PCa) is often driven by genetic and epigenetic aberrations in the androgen receptor (AR) and coregulators that maintain androgen signaling activity. We show that specific small RNAs downregulate
Externí odkaz:
https://doaj.org/article/7f27fc30f9d341459f7710042befb4d8
Autor:
Jennifer W. Tsai, MD, M.Ed, Jessica P. Cerdeña, M.Phil, William C. Goedel, PhD, William S. Asch, MD, PhD, Vanessa Grubbs, MD, MPH, Mallika L. Mendu, MD, MBA, Jay S. Kaufman, PhD
Publikováno v:
EClinicalMedicine, Vol 42, Iss , Pp 101197- (2021)
ABSTRACT: Background: Standard equations for estimating glomerular filtration rate (eGFR) employ race multipliers, systematically inflating eGFR for Black patients. Such inflation is clinically significant because eGFR thresholds of 60, 30, and 20 ml
Externí odkaz:
https://doaj.org/article/b1908a9d5bf042828998bedc6423665c
Autor:
David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence J. Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany N. Tanaka, Joshua F. Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Rami Komrokji, Jeffrey Lancet, Hagop M. Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G. Daver
Publikováno v:
Journal of Clinical Oncology. 41:2815-2826
PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells
Publikováno v:
Future Science OA, Vol 6, Iss 7 (2020)
Background: Immune-related adverse events are associated with efficacy of immune checkpoint inhibitors (ICIs). We hypothesize that immune-mediated thrombocytopenia could be a biomarker for response to ICIs. Materials & methods: This retrospective stu
Externí odkaz:
https://doaj.org/article/4dd001446d8248e181b2ec45db483397